What is AMH?
Anti-Müllerian hormone (AMH) is a key biochemical marker for assessing ovarian reserve in women. It is primarily secreted by granulosa cells of pre-antral and small antral follicles, and its serum concentration reflects the pool of recruitable follicles within the ovaries. It is essential to distinguish that AMH indicates the current size of the growing follicle cohort rather than the lifelong stock of primordial follicles. The primordial follicle pool undergoes irreversible age-related depletion. Therefore, evaluation of ovarian reserve should focus on both the quantity and quality of the presently available recruitable follicles.
Why does the AMH fluctuate?
Clinical observations demonstrate that certain interventions may produce a transient rise in AMH values. This increase results from the recruitment of previously quiescent follicles into the growing phase, thereby enlarging the population of AMH-producing follicles. Such changes indicate optimisation of follicular development dynamics rather than an expansion of the primordial follicle pool. For women whose AMH levels suggest diminished ovarian reserve, this improvement represents a limited but clinically meaningful intervention window during which enhancement of follicular quality may improve conception probability. The AMH value fluctuates, a characteristic that supports its utility as a dynamic monitoring tool.
From the perspective of mechanism of action, specific nutritional interventions can affect the microenvironment for follicle development. Juvenex Reco18, for example, contains the patented active compound Reco18, the mechanism of which has been published in peer-reviewed literature.
This compound acts through three principal pathways:
- supporting granulosa-cell function and nutrient delivery to the oocyte;
- maintaining normal cellular energy metabolism;
- preserving redox homeostasis.
The combined effect optimises the follicular microenvironment.
For women prioritising reproductive health, understanding the clinical significance of AMH is critical. An AMH value indicating the need for attention to ovarian reserve signals a relatively limited pool of recruitable follicles. At this point, evidence-based interventions become particularly relevant. Juvenex Reco18, developed on the basis of defined physiological mechanisms, is designed to provide targeted nutritional support to key stages of follicular development. Any intervention must be undertaken under professional medical guidance and tailored to the individual patient.
In reproductive health management, AMH serves as an important indicator of ovarian reserve, and its trajectory merits close attention. Fertility preservation, however, is multifactorial. Combining AMH monitoring with additional assessment modalities provides a more comprehensive foundation for fertility planning decisions. Products such as Juvenex Reco18 may be incorporated as an adjunctive component of an overall health strategy, under specialist supervision, to support follicular health and development.
Assessment and management of ovarian reserve require scientific understanding combined with appropriate intervention. Changes in AMH offer a valuable window into follicular dynamics, while evidence-based measures such as Juvenex Reco18 provide a rational approach to optimising the follicular microenvironment. Final decisions should always be guided by individualised medical evaluation and expert reproductive counselling.
